Sisira Yadala

Associate Professor

University of Arkansas for Medical Sciences

faculty

Neurology, College of Medicine

7 h-index 39 pubs 410 cited

Research Areas

Links

ORCID Lab Website UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Dr. Sisira Yadala's research focuses on neurological disorders, with a particular emphasis on epilepsy and its management. Her work investigates various therapeutic strategies, including neuro-modulation with devices like Vagal Nerve Stimulators (VNS), Responsive Neurostimulation (RNS), and Deep Brain Stimulation (DBS). Dr. Yadala also studies the treatment of refractory epilepsy, a condition characterized by seizures that are difficult to control with standard medications.

Her clinical interests extend to the pre-surgical evaluation for epilepsy surgery and the specific considerations for epilepsy in women. Dr. Yadala has contributed to the literature through systematic reviews, including one on Thrombotic Thrombocytopenic Purpura (TTP) after COVID-19 vaccination, and has explored topics such as the predictors of no-show appointments in neurology clinics and the continued underutilization of stroke care during the COVID-19 pandemic. Her publications also touch upon neuroanatomy and the use of Everolimus for refractory seizures in Tuberous Sclerosis, as well as acute disruption of cortical epileptiform discharges with thalamic stimulation. Dr. Yadala's scholarly output includes 39 publications, an h-index of 7, and over 410 citations.

Research Overview

Dr. Sisira Yadala is an Assistant Professor of Neurology and Director of the Division of Epilepsy and Level 4 Comprehensive Epilepsy Center at the University of Arkansas for Medical Sciences (UAMS). Dr. Yadala is board certified by the Board of Psychiatry and Neurology in both Neurology and Epilepsy. Dr. Yadala graduated from Osmania Medical College, Hyderabad, India in 2007. She then completed a Preliminary Internal Medicine Residency at West Lake Hospital, Resurrection Health Systems, Melrose Park, Illinois in 2010 prior to joining the Temple University Hospital in Philadelphia, Pennsylvania where she completed her Neurology Residency in 2013, followed by completion of a Epilepsy/Clinical Neurophysiology Fellowship at New York University, New York, New York in 2014. Dr.Yadala’s expertise and clinical interests include management of refractory epilepsy (difficult to control epilepsy) , Video EEG monitoring, Invasive EEG monitoring, Pre-surgical evaluation for epilepsy surgery, Neuro-modulation with devices such as VNS (Vagal Nerve Stimulator), RNS (Responsive Neurostimulation) and DBS (Deep Brain Stimulation) and Epilepsy in women. Dr.Yadala treats patients at the Freeway Epilepsy and Neurology clinic.

Metrics

h-index: 7
Publications: 39
Citations: 410

Selected Publications

Acute Disruption of Cortical Epileptiform Discharges With Thalamic Stimulation (2025) DOI
Vagus nerve stimulation for the management of epilepsy (2024) DOI
Approach to patients with autoimmune encephalitis with no identifiable antibodies (P2-1.001) (2022) DOI
Everolimus for Treatment of Refractory Seizures in Tuberous Sclerosis (P3-8.002) (2022) DOI
A case report of Granulomatous angiitis associated with Cogan syndrome. (P12-1.002) (2022) DOI
Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: A systematic review of reported cases (2022) DOI
Predictors of No-Show in Neurology Clinics (2022) DOI
Continued Underutilization of stroke care during the COVID-19 pandemic (2021) DOI
A 44-Year-Old Woman With a 10-Year History of Dyspnea and Pulmonary Nodules (2021) DOI
Neuroanatomy, Corticobulbar Tract (2021)
EEG Benign Variants (2021)

Grants & Funding

A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of intravenous ganaxolone in status epilepticus (IRB 262680) Marinus Pharmaceuticals Principal Investigator
A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of intravenous ganaxolone in status epilepticus (IRB 262680) Marinus Pharmaceuticals Principal Investigator